title: Mobilization of peripheral blood stem cells in patients with advanced thoracic malignancies after irinotecan (CPT-11) administration.
abstract: We evaluated the mobilization of peripheral blood stem cells (PBSCs) after the administration of chemotherapy including irinotecan (CPT-11) in individuals with advanced thoracic malignancies including lung cancer and mesothelioma. All patients were previously untreated. The numbers of CD34+ cells, CD34+ 38- cells, and colony-forming units granulocyte-macrophage (CFU-GM) in peripheral blood were determined to monitor PBSCs at least twice a week. Granulocyte colony-stimulating factor (G-CSF) (75 micrograms/body per day) was administered at the onset of neutropenia [absolute neutrophil count (ANC) of < 1000/microliter] until the ANC exceeded 5000/microliter. In patients who received G-CSF, sufficient counts of the PBSCs for PBSC transplantation were mobilized at the time when the white blood cell count was > 5000/microliter. CPT-11 with G-CSF is thus a promising induction regimen for PBSC transplantation. Patients who did not develop neutropenia after chemotherapy showed a significantly (p = 0.005) higher number of CD34+ cells in the peripheral blood at steady state (median, 1818; range, 1534 to 4433; n = 8) than those who developed neutropenia (median, 666; range, 608 to 1553; n = 5). This parameter may thus prove a useful marker for predicting neutropenia after the administration of CPT-11.
authors.affiliation: Second Department of Internal Medicine, Hiroshima University School of Medicine, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Egusa
authors.forename: Y
authors.initials: Y
authors.lastname: Fujiwara
authors.forename: E
authors.initials: E
authors.lastname: Syaharuddin
authors.forename: H
authors.initials: H
authors.lastname: Sumiyoshi
authors.forename: T
authors.initials: T
authors.lastname: Isobe
authors.forename: M
authors.initials: M
authors.lastname: Yamakido
mesh_terms: D036541:ADP-ribosyl Cyclase; D051997:ADP-ribosyl Cyclase 1; D000368:Aged; D015703:Antigens, CD; D018952:Antigens, CD34; D000943:Antigens, Differentiation; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D001772:Blood Cell Count; D002166:Camptothecin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003114:Colony-Forming Units Assay; D019650:Hematopoietic Stem Cell Mobilization; D006412:Hematopoietic Stem Cells; D006801:Humans; D000077146:Irinotecan; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000628:therapy; D008297:Male; D008562:Membrane Glycoproteins; D008654:Mesothelioma / Q000188:drug therapy* / Q000628:therapy; D008875:Middle Aged; D009244:NAD+ Nucleosidase; D009503:Neutropenia / Q000139:chemically induced; D059004:Topoisomerase I Inhibitors
chemical_list: D015703:Antigens, CD; D018952:Antigens, CD34; D000943:Antigens, Differentiation; D000972:Antineoplastic Agents, Phytogenic; D008562:Membrane Glycoproteins; D059004:Topoisomerase I Inhibitors; D000077146:Irinotecan; D036541:ADP-ribosyl Cyclase; C498154:CD38 protein, human; D009244:NAD+ Nucleosidase; D051997:ADP-ribosyl Cyclase 1; D002166:Camptothecin